CAMP4 Therapeutics Corp (CAMP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.41-1.78%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CAMP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 120.2% |
| Our one-year growth estimate | diamond | 4.5% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 115.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CAMP — private placement
Dated 2026-08-04
Entry into a Material Definitive Agreement. As previously disclosed in its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “Commission”) on September 10, 2025, CAMP4 Therapeutics Corporation (the “Company”) entered into a Securities Purchase Agreement, dated September 9, 2025 (the “Original Agreement”), with certain accredited investors named therein (each, an “Investor” and collectively, the “Investors”), pursuant to which the Company agreed to sell to…
Why it matters: CAMP operates in a maturing sector. Changes in sector growth can impact CAMP's performance and investor sentiment.
Watch forHealth Care sector revenue growth re-accelerates back toward its highs.
Also watch forSector growth continues to slow down. This shows wider problems in the Health Care industry.
Why it matters: This event will show details about the clinical trial and early plans. It may affect how investors feel.
Watch forAnalysts and investors liked the trial design. They also liked the updates.
Also watch forThere are concerns about the trial design or updates.
Why it matters: This report will show how CAMP4 is managing its finances and progress on trials.
Watch forThe earnings report shows more money made or smaller losses than before.
Also watch forEarnings report shows increased losses or stagnant revenue.
Why it matters: Maintaining a cash runway through 2028 is crucial for funding ongoing trials and operations. It reflects financial health.
Supportive ifManagement says they have enough cash to fund activities until 2028.
Worry ifManagement says they will need more money before 2028.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$345 on $10,000 · ±3.4% | How much price usually moves either way. |
| Bad day | $932 loss on $10,000 · 9.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,778 loss on $10,000 · 57.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: More regulatory filings could expand the trial's reach and increase patient enrollment. This is key for the drug's development.
Supportive ifCAMP4 has new regulatory filings. These will help enroll more people in the CMP-002 trial.
Worry ifIf no new regulatory filings are made, there will be fewer enrollment chances.
Why it matters: Changes to the incentive plan can change how motivated management is. Investors want management and shareholders to share the same goals.
Watch forMore details will show how the new plan changes executive pay and performance measures.
Also watch forNo new information is given. This creates doubt about how well management aligns with shareholders.
Why it matters: If healthcare revenue growth drops, it may impact CAMP4's performance.
Worry ifHealthcare revenue growth falls below its median rate.
Less concerning ifHealthcare revenue growth remains stable or improves.
Why it matters: Starting this trial is key for CAMP4's growth and future product pipeline. It shows progress in their research efforts.
Supportive ifA press release confirming the start of the global Phase 1/2 trial for SYNGAP1.
Worry ifNo announcement or delay in starting the global Phase 1/2 trial for SYNGAP1.
Why it matters: CAMP4 needs to manage its cash well to stay funded into 2028. This affects their operations.
Worry ifA quarterly report showing cash burn is less than $18 million.
Less concerning ifCash burn exceeds $18 million in the next quarterly report.
Why it matters: Starting this trial is a key step for CMP-002 in treating SYNGAP1 disorder. It shows progress in developing a treatment for a condition with no approved therapies.
Supportive ifThe Phase 1/2 clinical trial of CMP-002 is initiated in Q4 2026 as planned.
Worry ifThe trial does not start as scheduled or is delayed beyond Q4 2026.
Why it matters: A strong cash position is important for funding trials and operations. It shows financial health.
Watch forCash runway confirmed to extend through the end of 2028.
Also watch forThe cash runway is shorter than expected. New financing may be needed sooner.
Why it matters: This event will provide insights into CMP-002's trial design and the company's pipeline. It may influence investor sentiment and expectations.
Watch forNew partnerships and good feedback were shared at the Virtual Analyst Day.
Also watch forNegative feedback or lack of new information during the event.